Introducing the Medicines and Medical Devices Access Initiative (MMD): a new collaboration that aims to improve patient access to safe, clinically and cost-effective healthcare products.
We explore the ongoing debate around NICE’s cost-effectiveness thresholds and what the future holds.
Dr Patterson, a GP working on the frontline of primary care, describes why he is encouraged by NICE's approval of tirzepatide (Mounjaro).
Colleagues in our Science Policy and Research Programme discuss their international research, paving the way for next generation health technology assessment.
5 ways NICE Advice can help you navigate this new opportunity alongside health technology assessment.
Our associate director of NICE Advice outlines his top tips for healthtech companies, helping them chart a clear path from innovation to NHS adoption.
Page 1 of 9